nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—CYP2E1—Dacarbazine—peripheral nervous system neoplasm	0.0843	0.148	CbGbCtD
Etoricoxib—PTGS2—Cisplatin—peripheral nervous system neoplasm	0.0643	0.113	CbGbCtD
Etoricoxib—PTGS2—Etoposide—peripheral nervous system neoplasm	0.0632	0.111	CbGbCtD
Etoricoxib—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.061	0.107	CbGbCtD
Etoricoxib—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0511	0.0897	CbGbCtD
Etoricoxib—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0487	0.0856	CbGbCtD
Etoricoxib—CYP2E1—Etoposide—peripheral nervous system neoplasm	0.0412	0.0724	CbGbCtD
Etoricoxib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0319	0.0561	CbGbCtD
Etoricoxib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0297	0.0522	CbGbCtD
Etoricoxib—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0238	0.0419	CbGbCtD
Etoricoxib—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0219	0.0384	CbGbCtD
Etoricoxib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0136	0.024	CbGbCtD
Etoricoxib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.0134	0.0235	CbGbCtD
Etoricoxib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0125	0.0219	CbGbCtD
Etoricoxib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00852	0.015	CbGbCtD
Etoricoxib—Vismodegib—ABCB1—peripheral nervous system neoplasm	0.000243	1	CrCbGaD
Etoricoxib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000153	0.00045	CcSEcCtD
Etoricoxib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000153	0.000449	CcSEcCtD
Etoricoxib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000152	0.000447	CcSEcCtD
Etoricoxib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000152	0.000447	CcSEcCtD
Etoricoxib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000444	CcSEcCtD
Etoricoxib—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.000443	CcSEcCtD
Etoricoxib—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000441	CcSEcCtD
Etoricoxib—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000438	CcSEcCtD
Etoricoxib—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000149	0.000438	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000437	CcSEcCtD
Etoricoxib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000437	CcSEcCtD
Etoricoxib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000148	0.000436	CcSEcCtD
Etoricoxib—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000436	CcSEcCtD
Etoricoxib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000148	0.000435	CcSEcCtD
Etoricoxib—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000148	0.000434	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000147	0.000433	CcSEcCtD
Etoricoxib—MAPK14—RANKL/RANK Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000146	0.00162	CbGpPWpGaD
Etoricoxib—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000429	CcSEcCtD
Etoricoxib—Pain—Cisplatin—peripheral nervous system neoplasm	0.000146	0.000429	CcSEcCtD
Etoricoxib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000428	CcSEcCtD
Etoricoxib—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000428	CcSEcCtD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000145	0.00161	CbGpPWpGaD
Etoricoxib—MAPK14—Thromboxane A2 receptor signaling—AKT1—peripheral nervous system neoplasm	0.000144	0.0016	CbGpPWpGaD
Etoricoxib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000144	0.000423	CcSEcCtD
Etoricoxib—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000422	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000421	CcSEcCtD
Etoricoxib—MAPK14—TSH signaling pathway—HRAS—peripheral nervous system neoplasm	0.000143	0.00159	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000142	0.000418	CcSEcCtD
Etoricoxib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000142	0.000417	CcSEcCtD
Etoricoxib—PTGS2—C-MYB transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000142	0.00157	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—HRAS—peripheral nervous system neoplasm	0.000141	0.00157	CbGpPWpGaD
Etoricoxib—MAPK14—BCR signaling pathway—HRAS—peripheral nervous system neoplasm	0.000141	0.00157	CbGpPWpGaD
Etoricoxib—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000414	CcSEcCtD
Etoricoxib—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000141	0.000414	CcSEcCtD
Etoricoxib—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000412	CcSEcCtD
Etoricoxib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000411	CcSEcCtD
Etoricoxib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000139	0.00041	CcSEcCtD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000139	0.00154	CbGpPWpGaD
Etoricoxib—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000409	CcSEcCtD
Etoricoxib—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000139	0.000409	CcSEcCtD
Etoricoxib—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000408	CcSEcCtD
Etoricoxib—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000139	0.000407	CcSEcCtD
Etoricoxib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000406	CcSEcCtD
Etoricoxib—MAPK14—Kit receptor signaling pathway—AKT1—peripheral nervous system neoplasm	0.000138	0.00153	CbGpPWpGaD
Etoricoxib—MAPK14—p53 pathway—AKT1—peripheral nervous system neoplasm	0.000138	0.00153	CbGpPWpGaD
Etoricoxib—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000404	CcSEcCtD
Etoricoxib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000404	CcSEcCtD
Etoricoxib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000137	0.000404	CcSEcCtD
Etoricoxib—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000403	CcSEcCtD
Etoricoxib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000137	0.000403	CcSEcCtD
Etoricoxib—MAPK14—CDC42 signaling events—HRAS—peripheral nervous system neoplasm	0.000137	0.00151	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000136	0.00151	CbGpPWpGaD
Etoricoxib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000401	CcSEcCtD
Etoricoxib—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000136	0.000401	CcSEcCtD
Etoricoxib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000136	0.0004	CcSEcCtD
Etoricoxib—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000397	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000135	0.000397	CcSEcCtD
Etoricoxib—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000135	0.000396	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000396	CcSEcCtD
Etoricoxib—MAPK14—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000135	0.00149	CbGpPWpGaD
Etoricoxib—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000394	CcSEcCtD
Etoricoxib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000394	CcSEcCtD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—MYC—peripheral nervous system neoplasm	0.000134	0.00148	CbGpPWpGaD
Etoricoxib—Pain—Etoposide—peripheral nervous system neoplasm	0.000134	0.000393	CcSEcCtD
Etoricoxib—Constipation—Etoposide—peripheral nervous system neoplasm	0.000134	0.000393	CcSEcCtD
Etoricoxib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000393	CcSEcCtD
Etoricoxib—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000393	CcSEcCtD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—NRAS—peripheral nervous system neoplasm	0.000133	0.00147	CbGpPWpGaD
Etoricoxib—MAPK14—IL4-mediated signaling events—AKT1—peripheral nervous system neoplasm	0.000133	0.00147	CbGpPWpGaD
Etoricoxib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.00039	CcSEcCtD
Etoricoxib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000133	0.00039	CcSEcCtD
Etoricoxib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000132	0.000388	CcSEcCtD
Etoricoxib—MAPK14—Endothelins—AKT1—peripheral nervous system neoplasm	0.000131	0.00145	CbGpPWpGaD
Etoricoxib—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000385	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—PTPN11—peripheral nervous system neoplasm	0.000131	0.00145	CbGpPWpGaD
Etoricoxib—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000383	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000382	CcSEcCtD
Etoricoxib—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000382	CcSEcCtD
Etoricoxib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000381	CcSEcCtD
Etoricoxib—MAPK14—Leptin signaling pathway—HRAS—peripheral nervous system neoplasm	0.000129	0.00143	CbGpPWpGaD
Etoricoxib—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000379	CcSEcCtD
Etoricoxib—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000129	0.000379	CcSEcCtD
Etoricoxib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000378	CcSEcCtD
Etoricoxib—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000128	0.000377	CcSEcCtD
Etoricoxib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000376	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000128	0.000376	CcSEcCtD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000128	0.00142	CbGpPWpGaD
Etoricoxib—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000128	0.000375	CcSEcCtD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000128	0.00141	CbGpPWpGaD
Etoricoxib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000127	0.000375	CcSEcCtD
Etoricoxib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000374	CcSEcCtD
Etoricoxib—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000374	CcSEcCtD
Etoricoxib—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000126	0.000371	CcSEcCtD
Etoricoxib—MAPK14—TSH signaling pathway—AKT1—peripheral nervous system neoplasm	0.000126	0.0014	CbGpPWpGaD
Etoricoxib—MAPK14—AGE/RAGE pathway—AKT1—peripheral nervous system neoplasm	0.000126	0.0014	CbGpPWpGaD
Etoricoxib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000126	0.000371	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000371	CcSEcCtD
Etoricoxib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000126	0.00037	CcSEcCtD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—TP53—peripheral nervous system neoplasm	0.000126	0.00139	CbGpPWpGaD
Etoricoxib—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000126	0.000369	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—NRAS—peripheral nervous system neoplasm	0.000125	0.00139	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000125	0.00139	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—ERBB2—peripheral nervous system neoplasm	0.000125	0.00139	CbGpPWpGaD
Etoricoxib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000368	CcSEcCtD
Etoricoxib—MAPK14—BDNF signaling pathway—CASP3—peripheral nervous system neoplasm	0.000125	0.00139	CbGpPWpGaD
Etoricoxib—MAPK14—BCR signaling pathway—AKT1—peripheral nervous system neoplasm	0.000125	0.00138	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—AKT1—peripheral nervous system neoplasm	0.000125	0.00138	CbGpPWpGaD
Etoricoxib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000367	CcSEcCtD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000124	0.00138	CbGpPWpGaD
Etoricoxib—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000124	0.000365	CcSEcCtD
Etoricoxib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000365	CcSEcCtD
Etoricoxib—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000364	CcSEcCtD
Etoricoxib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000364	CcSEcCtD
Etoricoxib—PTGS2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000124	0.00137	CbGpPWpGaD
Etoricoxib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000124	0.000363	CcSEcCtD
Etoricoxib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000363	CcSEcCtD
Etoricoxib—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000363	CcSEcCtD
Etoricoxib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000363	CcSEcCtD
Etoricoxib—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000363	CcSEcCtD
Etoricoxib—MAPK14—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—peripheral nervous system neoplasm	0.000123	0.00137	CbGpPWpGaD
Etoricoxib—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000361	CcSEcCtD
Etoricoxib—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000123	0.000361	CcSEcCtD
Etoricoxib—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000123	0.00036	CcSEcCtD
Etoricoxib—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000123	0.00036	CcSEcCtD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	0.000122	0.00135	CbGpPWpGaD
Etoricoxib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000358	CcSEcCtD
Etoricoxib—Rash—Vincristine—peripheral nervous system neoplasm	0.000122	0.000358	CcSEcCtD
Etoricoxib—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000122	0.000358	CcSEcCtD
Etoricoxib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000357	CcSEcCtD
Etoricoxib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000357	CcSEcCtD
Etoricoxib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000356	CcSEcCtD
Etoricoxib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000356	CcSEcCtD
Etoricoxib—Headache—Vincristine—peripheral nervous system neoplasm	0.000121	0.000356	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000354	CcSEcCtD
Etoricoxib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000353	CcSEcCtD
Etoricoxib—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000351	CcSEcCtD
Etoricoxib—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000119	0.00035	CcSEcCtD
Etoricoxib—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000119	0.00035	CcSEcCtD
Etoricoxib—MAPK14—Immune System—CD55—peripheral nervous system neoplasm	0.000117	0.0013	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—CDKN2A—peripheral nervous system neoplasm	0.000117	0.0013	CbGpPWpGaD
Etoricoxib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000117	0.000343	CcSEcCtD
Etoricoxib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000343	CcSEcCtD
Etoricoxib—CYP2E1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000117	0.00129	CbGpPWpGaD
Etoricoxib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000339	CcSEcCtD
Etoricoxib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000115	0.000339	CcSEcCtD
Etoricoxib—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000338	CcSEcCtD
Etoricoxib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000337	CcSEcCtD
Etoricoxib—Nausea—Vincristine—peripheral nervous system neoplasm	0.000115	0.000337	CcSEcCtD
Etoricoxib—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000337	CcSEcCtD
Etoricoxib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000337	CcSEcCtD
Etoricoxib—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000336	CcSEcCtD
Etoricoxib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000336	CcSEcCtD
Etoricoxib—MAPK14—Leptin signaling pathway—AKT1—peripheral nervous system neoplasm	0.000114	0.00126	CbGpPWpGaD
Etoricoxib—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000334	CcSEcCtD
Etoricoxib—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000333	CcSEcCtD
Etoricoxib—MAPK14—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000113	0.00125	CbGpPWpGaD
Etoricoxib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000331	CcSEcCtD
Etoricoxib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000331	CcSEcCtD
Etoricoxib—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000112	0.00033	CcSEcCtD
Etoricoxib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.00033	CcSEcCtD
Etoricoxib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000329	CcSEcCtD
Etoricoxib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000329	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000112	0.00124	CbGpPWpGaD
Etoricoxib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000328	CcSEcCtD
Etoricoxib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000327	CcSEcCtD
Etoricoxib—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000111	0.000325	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—CASP3—peripheral nervous system neoplasm	0.000111	0.00122	CbGpPWpGaD
Etoricoxib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000324	CcSEcCtD
Etoricoxib—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000323	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.00011	0.00122	CbGpPWpGaD
Etoricoxib—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000321	CcSEcCtD
Etoricoxib—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000109	0.000319	CcSEcCtD
Etoricoxib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000318	CcSEcCtD
Etoricoxib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000317	CcSEcCtD
Etoricoxib—Rash—Cisplatin—peripheral nervous system neoplasm	0.000108	0.000316	CcSEcCtD
Etoricoxib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000108	0.000316	CcSEcCtD
Etoricoxib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000316	CcSEcCtD
Etoricoxib—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000316	CcSEcCtD
Etoricoxib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000107	0.000315	CcSEcCtD
Etoricoxib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000314	CcSEcCtD
Etoricoxib—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000313	CcSEcCtD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000106	0.00118	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—AKT1—peripheral nervous system neoplasm	0.000106	0.00118	CbGpPWpGaD
Etoricoxib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000312	CcSEcCtD
Etoricoxib—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000312	CcSEcCtD
Etoricoxib—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000311	CcSEcCtD
Etoricoxib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000309	CcSEcCtD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000105	0.00117	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000105	0.00116	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—MYC—peripheral nervous system neoplasm	0.000105	0.00116	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—AKT1—peripheral nervous system neoplasm	0.000104	0.00115	CbGpPWpGaD
Etoricoxib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000305	CcSEcCtD
Etoricoxib—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000103	0.000304	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—ERBB2—peripheral nervous system neoplasm	0.000103	0.00115	CbGpPWpGaD
Etoricoxib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000304	CcSEcCtD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—TP53—peripheral nervous system neoplasm	0.000103	0.00114	CbGpPWpGaD
Etoricoxib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000303	CcSEcCtD
Etoricoxib—PTGS2—C-MYB transcription factor network—NRAS—peripheral nervous system neoplasm	0.000103	0.00114	CbGpPWpGaD
Etoricoxib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000303	CcSEcCtD
Etoricoxib—MAPK14—Regulation of mRNA stability by proteins that bind AU-rich elements—AKT1—peripheral nervous system neoplasm	0.000102	0.00113	CbGpPWpGaD
Etoricoxib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.0003	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—IFNB1—peripheral nervous system neoplasm	0.000102	0.00113	CbGpPWpGaD
Etoricoxib—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000101	0.000298	CcSEcCtD
Etoricoxib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000298	CcSEcCtD
Etoricoxib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000297	CcSEcCtD
Etoricoxib—MAPK14—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	0.000101	0.00112	CbGpPWpGaD
Etoricoxib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000294	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	9.97e-05	0.00111	CbGpPWpGaD
Etoricoxib—Vomiting—Etoposide—peripheral nervous system neoplasm	9.95e-05	0.000292	CcSEcCtD
Etoricoxib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	9.94e-05	0.000292	CcSEcCtD
Etoricoxib—Erythema—Doxorubicin—peripheral nervous system neoplasm	9.94e-05	0.000292	CcSEcCtD
Etoricoxib—Anaemia—Epirubicin—peripheral nervous system neoplasm	9.93e-05	0.000292	CcSEcCtD
Etoricoxib—Agitation—Epirubicin—peripheral nervous system neoplasm	9.87e-05	0.00029	CcSEcCtD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—HRAS—peripheral nervous system neoplasm	9.87e-05	0.00109	CbGpPWpGaD
Etoricoxib—Rash—Etoposide—peripheral nervous system neoplasm	9.86e-05	0.00029	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—AKT1—peripheral nervous system neoplasm	9.86e-05	0.00109	CbGpPWpGaD
Etoricoxib—Dermatitis—Etoposide—peripheral nervous system neoplasm	9.85e-05	0.00029	CcSEcCtD
Etoricoxib—Headache—Etoposide—peripheral nervous system neoplasm	9.8e-05	0.000288	CcSEcCtD
Etoricoxib—Flatulence—Doxorubicin—peripheral nervous system neoplasm	9.8e-05	0.000288	CcSEcCtD
Etoricoxib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	9.74e-05	0.000286	CcSEcCtD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—HRAS—peripheral nervous system neoplasm	9.72e-05	0.00108	CbGpPWpGaD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—AKT1—peripheral nervous system neoplasm	9.69e-05	0.00107	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—MYC—peripheral nervous system neoplasm	9.6e-05	0.00106	CbGpPWpGaD
Etoricoxib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	9.56e-05	0.000281	CcSEcCtD
Etoricoxib—Palpitations—Epirubicin—peripheral nervous system neoplasm	9.5e-05	0.000279	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	9.44e-05	0.00105	CbGpPWpGaD
Etoricoxib—Cough—Epirubicin—peripheral nervous system neoplasm	9.38e-05	0.000276	CcSEcCtD
Etoricoxib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	9.37e-05	0.000275	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	9.37e-05	0.00104	CbGpPWpGaD
Etoricoxib—MAPK14—Oxidative Stress Induced Senescence—TP53—peripheral nervous system neoplasm	9.34e-05	0.00103	CbGpPWpGaD
Etoricoxib—Nausea—Etoposide—peripheral nervous system neoplasm	9.29e-05	0.000273	CcSEcCtD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	9.28e-05	0.00103	CbGpPWpGaD
Etoricoxib—Hypertension—Epirubicin—peripheral nervous system neoplasm	9.28e-05	0.000273	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—NRAS—peripheral nervous system neoplasm	9.26e-05	0.00103	CbGpPWpGaD
Etoricoxib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	9.19e-05	0.00027	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—HRAS—peripheral nervous system neoplasm	9.18e-05	0.00102	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—GNAS—peripheral nervous system neoplasm	9.18e-05	0.00102	CbGpPWpGaD
Etoricoxib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	9.15e-05	0.000269	CcSEcCtD
Etoricoxib—Chest pain—Epirubicin—peripheral nervous system neoplasm	9.15e-05	0.000269	CcSEcCtD
Etoricoxib—Agitation—Doxorubicin—peripheral nervous system neoplasm	9.14e-05	0.000269	CcSEcCtD
Etoricoxib—Anxiety—Epirubicin—peripheral nervous system neoplasm	9.12e-05	0.000268	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	9.08e-05	0.000267	CcSEcCtD
Etoricoxib—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.99e-05	0.000997	CbGpPWpGaD
Etoricoxib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	8.95e-05	0.000263	CcSEcCtD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	8.92e-05	0.000988	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD34—peripheral nervous system neoplasm	8.9e-05	0.000986	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	8.87e-05	0.000983	CbGpPWpGaD
Etoricoxib—Confusional state—Epirubicin—peripheral nervous system neoplasm	8.84e-05	0.00026	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	8.79e-05	0.000974	CbGpPWpGaD
Etoricoxib—Palpitations—Doxorubicin—peripheral nervous system neoplasm	8.79e-05	0.000258	CcSEcCtD
Etoricoxib—Oedema—Epirubicin—peripheral nervous system neoplasm	8.77e-05	0.000258	CcSEcCtD
Etoricoxib—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	8.77e-05	0.000258	CcSEcCtD
Etoricoxib—MAPK14—Hemostasis—HGF—peripheral nervous system neoplasm	8.74e-05	0.000969	CbGpPWpGaD
Etoricoxib—Infection—Epirubicin—peripheral nervous system neoplasm	8.71e-05	0.000256	CcSEcCtD
Etoricoxib—Cough—Doxorubicin—peripheral nervous system neoplasm	8.68e-05	0.000255	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	8.63e-05	0.000956	CbGpPWpGaD
Etoricoxib—Shock—Epirubicin—peripheral nervous system neoplasm	8.63e-05	0.000254	CcSEcCtD
Etoricoxib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	8.6e-05	0.000253	CcSEcCtD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—TP53—peripheral nervous system neoplasm	8.59e-05	0.000952	CbGpPWpGaD
Etoricoxib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	8.59e-05	0.000252	CcSEcCtD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	8.58e-05	0.000951	CbGpPWpGaD
Etoricoxib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	8.58e-05	0.000252	CcSEcCtD
Etoricoxib—MAPK14—Immune System—PPP3R1—peripheral nervous system neoplasm	8.56e-05	0.000949	CbGpPWpGaD
Etoricoxib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	8.52e-05	0.00025	CcSEcCtD
Etoricoxib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	8.46e-05	0.000249	CcSEcCtD
Etoricoxib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	8.46e-05	0.000249	CcSEcCtD
Etoricoxib—Anxiety—Doxorubicin—peripheral nervous system neoplasm	8.43e-05	0.000248	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	8.41e-05	0.000247	CcSEcCtD
Etoricoxib—PTGS2—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.37e-05	0.000927	CbGpPWpGaD
Etoricoxib—Anorexia—Epirubicin—peripheral nervous system neoplasm	8.36e-05	0.000246	CcSEcCtD
Etoricoxib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	8.28e-05	0.000243	CcSEcCtD
Etoricoxib—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.27e-05	0.000917	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.2e-05	0.000909	CbGpPWpGaD
Etoricoxib—Confusional state—Doxorubicin—peripheral nervous system neoplasm	8.18e-05	0.00024	CcSEcCtD
Etoricoxib—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	8.11e-05	0.000238	CcSEcCtD
Etoricoxib—Oedema—Doxorubicin—peripheral nervous system neoplasm	8.11e-05	0.000238	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	8.1e-05	0.000898	CbGpPWpGaD
Etoricoxib—Infection—Doxorubicin—peripheral nervous system neoplasm	8.06e-05	0.000237	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	7.99e-05	0.000235	CcSEcCtD
Etoricoxib—Shock—Doxorubicin—peripheral nervous system neoplasm	7.98e-05	0.000235	CcSEcCtD
Etoricoxib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	7.96e-05	0.000234	CcSEcCtD
Etoricoxib—MAPK14—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	7.95e-05	0.000881	CbGpPWpGaD
Etoricoxib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	7.94e-05	0.000233	CcSEcCtD
Etoricoxib—Insomnia—Epirubicin—peripheral nervous system neoplasm	7.93e-05	0.000233	CcSEcCtD
Etoricoxib—MAPK14—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.92e-05	0.000877	CbGpPWpGaD
Etoricoxib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	7.88e-05	0.000232	CcSEcCtD
Etoricoxib—CYP2E1—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.88e-05	0.000873	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	7.87e-05	0.000872	CbGpPWpGaD
Etoricoxib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	7.82e-05	0.00023	CcSEcCtD
Etoricoxib—Somnolence—Epirubicin—peripheral nervous system neoplasm	7.8e-05	0.000229	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	7.79e-05	0.000863	CbGpPWpGaD
Etoricoxib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	7.73e-05	0.000227	CcSEcCtD
Etoricoxib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	7.72e-05	0.000227	CcSEcCtD
Etoricoxib—MAPK14—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	7.67e-05	0.000849	CbGpPWpGaD
Etoricoxib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	7.62e-05	0.000224	CcSEcCtD
Etoricoxib—MAPK14—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.59e-05	0.000841	CbGpPWpGaD
Etoricoxib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	7.57e-05	0.000223	CcSEcCtD
Etoricoxib—MAPK14—Immune System—NCAM1—peripheral nervous system neoplasm	7.56e-05	0.000838	CbGpPWpGaD
Etoricoxib—Fatigue—Epirubicin—peripheral nervous system neoplasm	7.56e-05	0.000222	CcSEcCtD
Etoricoxib—PTGS2—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	7.54e-05	0.000835	CbGpPWpGaD
Etoricoxib—Constipation—Epirubicin—peripheral nervous system neoplasm	7.5e-05	0.00022	CcSEcCtD
Etoricoxib—Pain—Epirubicin—peripheral nervous system neoplasm	7.5e-05	0.00022	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	7.39e-05	0.000217	CcSEcCtD
Etoricoxib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	7.34e-05	0.000216	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	7.31e-05	0.00081	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—AKT1—peripheral nervous system neoplasm	7.26e-05	0.000804	CbGpPWpGaD
Etoricoxib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	7.23e-05	0.000213	CcSEcCtD
Etoricoxib—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	7.23e-05	0.000212	CcSEcCtD
Etoricoxib—PTGS2—Disease—GNS—peripheral nervous system neoplasm	7.22e-05	0.0008	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—CASP3—peripheral nervous system neoplasm	7.22e-05	0.0008	CbGpPWpGaD
Etoricoxib—Somnolence—Doxorubicin—peripheral nervous system neoplasm	7.21e-05	0.000212	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	7.17e-05	0.000211	CcSEcCtD
Etoricoxib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	7.14e-05	0.00021	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	7.09e-05	0.000785	CbGpPWpGaD
Etoricoxib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	7.05e-05	0.000207	CcSEcCtD
Etoricoxib—MAPK14—Insulin Signaling—HRAS—peripheral nervous system neoplasm	7.05e-05	0.000781	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MET—peripheral nervous system neoplasm	7.03e-05	0.000779	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	7.02e-05	0.000778	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.01e-05	0.000777	CbGpPWpGaD
Etoricoxib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	7e-05	0.000206	CcSEcCtD
Etoricoxib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	7e-05	0.000206	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	6.98e-05	0.000773	CbGpPWpGaD
Etoricoxib—Urticaria—Epirubicin—peripheral nervous system neoplasm	6.97e-05	0.000205	CcSEcCtD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	6.96e-05	0.000772	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	6.95e-05	0.00077	CbGpPWpGaD
Etoricoxib—Constipation—Doxorubicin—peripheral nervous system neoplasm	6.94e-05	0.000204	CcSEcCtD
Etoricoxib—Pain—Doxorubicin—peripheral nervous system neoplasm	6.94e-05	0.000204	CcSEcCtD
Etoricoxib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	6.93e-05	0.000204	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	6.9e-05	0.000765	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	6.77e-05	0.00075	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	6.69e-05	0.000197	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	6.63e-05	0.000195	CcSEcCtD
Etoricoxib—MAPK14—Cellular Senescence—TP53—peripheral nervous system neoplasm	6.53e-05	0.000724	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—PTPN11—peripheral nervous system neoplasm	6.5e-05	0.00072	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	6.46e-05	0.00019	CcSEcCtD
Etoricoxib—Urticaria—Doxorubicin—peripheral nervous system neoplasm	6.45e-05	0.000189	CcSEcCtD
Etoricoxib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	6.41e-05	0.000189	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	6.39e-05	0.000709	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—PTPN11—peripheral nervous system neoplasm	6.38e-05	0.000707	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	6.37e-05	0.000706	CbGpPWpGaD
Etoricoxib—Asthenia—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.000185	CcSEcCtD
Etoricoxib—MAPK14—Insulin Signaling—AKT1—peripheral nervous system neoplasm	6.22e-05	0.000689	CbGpPWpGaD
Etoricoxib—Pruritus—Epirubicin—peripheral nervous system neoplasm	6.2e-05	0.000182	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	6.16e-05	0.000683	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.08e-05	0.000673	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—NRAS—peripheral nervous system neoplasm	6.05e-05	0.000671	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GNS—peripheral nervous system neoplasm	6.05e-05	0.00067	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	6e-05	0.000665	CbGpPWpGaD
Etoricoxib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	6e-05	0.000176	CcSEcCtD
Etoricoxib—MAPK14—Signaling Pathways—VIP—peripheral nervous system neoplasm	6e-05	0.000665	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	5.98e-05	0.000663	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	5.98e-05	0.000176	CcSEcCtD
Etoricoxib—MAPK14—Immune System—IFNB1—peripheral nervous system neoplasm	5.94e-05	0.000658	CbGpPWpGaD
Etoricoxib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000171	CcSEcCtD
Etoricoxib—PTGS2—Metabolism—NME1—peripheral nervous system neoplasm	5.8e-05	0.000643	CbGpPWpGaD
Etoricoxib—Dizziness—Epirubicin—peripheral nervous system neoplasm	5.8e-05	0.00017	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	5.76e-05	0.000638	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PTPN11—peripheral nervous system neoplasm	5.74e-05	0.000636	CbGpPWpGaD
Etoricoxib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000169	CcSEcCtD
Etoricoxib—CYP2E1—Metabolism—GNS—peripheral nervous system neoplasm	5.69e-05	0.000631	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.59e-05	0.000619	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—COX2—peripheral nervous system neoplasm	5.58e-05	0.000619	CbGpPWpGaD
Etoricoxib—Vomiting—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.000164	CcSEcCtD
Etoricoxib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	5.55e-05	0.000163	CcSEcCtD
Etoricoxib—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.54e-05	0.000614	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.54e-05	0.000614	CbGpPWpGaD
Etoricoxib—Rash—Epirubicin—peripheral nervous system neoplasm	5.53e-05	0.000163	CcSEcCtD
Etoricoxib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	5.52e-05	0.000162	CcSEcCtD
Etoricoxib—Headache—Epirubicin—peripheral nervous system neoplasm	5.49e-05	0.000161	CcSEcCtD
Etoricoxib—CYP2E1—Metabolism—NME1—peripheral nervous system neoplasm	5.46e-05	0.000605	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.41e-05	0.000599	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.4e-05	0.000598	CbGpPWpGaD
Etoricoxib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	5.37e-05	0.000158	CcSEcCtD
Etoricoxib—CYP2E1—Metabolism—COX2—peripheral nervous system neoplasm	5.25e-05	0.000582	CbGpPWpGaD
Etoricoxib—Nausea—Epirubicin—peripheral nervous system neoplasm	5.21e-05	0.000153	CcSEcCtD
Etoricoxib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	5.16e-05	0.000152	CcSEcCtD
Etoricoxib—MAPK14—Developmental Biology—ERBB2—peripheral nervous system neoplasm	5.14e-05	0.000569	CbGpPWpGaD
Etoricoxib—Rash—Doxorubicin—peripheral nervous system neoplasm	5.12e-05	0.00015	CcSEcCtD
Etoricoxib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	5.11e-05	0.00015	CcSEcCtD
Etoricoxib—Headache—Doxorubicin—peripheral nervous system neoplasm	5.08e-05	0.000149	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	5.08e-05	0.000563	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PPP3R1—peripheral nervous system neoplasm	5.05e-05	0.00056	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.05e-05	0.00056	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	4.97e-05	0.000551	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—TP53—peripheral nervous system neoplasm	4.94e-05	0.000547	CbGpPWpGaD
Etoricoxib—MAPK14—Metabolism of mRNA—AKT1—peripheral nervous system neoplasm	4.84e-05	0.000536	CbGpPWpGaD
Etoricoxib—Nausea—Doxorubicin—peripheral nervous system neoplasm	4.82e-05	0.000142	CcSEcCtD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	4.8e-05	0.000532	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.73e-05	0.000525	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.6e-05	0.00051	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HGF—peripheral nervous system neoplasm	4.58e-05	0.000508	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—ERBB2—peripheral nervous system neoplasm	4.54e-05	0.000503	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—HRAS—peripheral nervous system neoplasm	4.43e-05	0.000491	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	4.39e-05	0.000487	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ENO2—peripheral nervous system neoplasm	4.38e-05	0.000485	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	4.21e-05	0.000467	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.16e-05	0.000461	CbGpPWpGaD
Etoricoxib—MAPK14—Metabolism of RNA—AKT1—peripheral nervous system neoplasm	4.14e-05	0.000459	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	4.08e-05	0.000453	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	4.05e-05	0.000449	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	4.04e-05	0.000448	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	4.01e-05	0.000444	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.93e-05	0.000436	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—AKT1—peripheral nervous system neoplasm	3.91e-05	0.000433	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.91e-05	0.000433	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	3.87e-05	0.000429	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	3.84e-05	0.000426	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—NRAS—peripheral nervous system neoplasm	3.83e-05	0.000425	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	3.73e-05	0.000413	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	3.7e-05	0.00041	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ENO2—peripheral nervous system neoplasm	3.66e-05	0.000406	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.65e-05	0.000405	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.56e-05	0.000394	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SLC2A1—peripheral nervous system neoplasm	3.53e-05	0.000391	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—NRAS—peripheral nervous system neoplasm	3.45e-05	0.000382	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ENO2—peripheral nervous system neoplasm	3.45e-05	0.000382	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	3.45e-05	0.000382	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	3.42e-05	0.000379	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.39e-05	0.000376	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PTPN11—peripheral nervous system neoplasm	3.34e-05	0.00037	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	3.28e-05	0.000364	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	3.16e-05	0.00035	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.11e-05	0.000345	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—BCHE—peripheral nervous system neoplasm	3.1e-05	0.000343	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.95e-05	0.000327	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TP53—peripheral nervous system neoplasm	2.93e-05	0.000325	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—BCHE—peripheral nervous system neoplasm	2.91e-05	0.000323	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—TH—peripheral nervous system neoplasm	2.91e-05	0.000323	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.86e-05	0.000317	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—HRAS—peripheral nervous system neoplasm	2.8e-05	0.000311	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.78e-05	0.000308	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—TH—peripheral nervous system neoplasm	2.74e-05	0.000304	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	2.66e-05	0.000295	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ERBB2—peripheral nervous system neoplasm	2.64e-05	0.000293	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	2.64e-05	0.000293	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	2.53e-05	0.000281	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HRAS—peripheral nervous system neoplasm	2.53e-05	0.00028	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.52e-05	0.00028	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—AKT1—peripheral nervous system neoplasm	2.48e-05	0.000274	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	2.45e-05	0.000271	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	2.44e-05	0.00027	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	2.43e-05	0.000269	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GNAS—peripheral nervous system neoplasm	2.38e-05	0.000263	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ABCB1—peripheral nervous system neoplasm	2.33e-05	0.000258	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	2.25e-05	0.000249	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GNAS—peripheral nervous system neoplasm	2.24e-05	0.000248	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.23e-05	0.000247	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.2e-05	0.000243	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.16e-05	0.00024	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.15e-05	0.000238	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	2.11e-05	0.000234	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	2.07e-05	0.00023	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	2.07e-05	0.000229	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	2.05e-05	0.000227	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NRAS—peripheral nervous system neoplasm	2.01e-05	0.000223	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.97e-05	0.000219	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PTPN11—peripheral nervous system neoplasm	1.97e-05	0.000219	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.96e-05	0.000217	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	1.94e-05	0.000215	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	1.93e-05	0.000214	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—peripheral nervous system neoplasm	1.86e-05	0.000206	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	1.75e-05	0.000194	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	1.73e-05	0.000191	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.71e-05	0.000189	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	1.69e-05	0.000188	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.67e-05	0.000185	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	1.65e-05	0.000183	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.6e-05	0.000177	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	1.59e-05	0.000176	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	1.57e-05	0.000174	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ERBB2—peripheral nervous system neoplasm	1.56e-05	0.000173	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	1.56e-05	0.000173	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.55e-05	0.000172	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.54e-05	0.000171	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HRAS—peripheral nervous system neoplasm	1.47e-05	0.000163	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.35e-05	0.00015	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.34e-05	0.000149	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.32e-05	0.000146	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.3e-05	0.000144	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—AKT1—peripheral nervous system neoplasm	1.3e-05	0.000144	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—AKT1—peripheral nervous system neoplasm	1.29e-05	0.000143	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.29e-05	0.000143	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.27e-05	0.000141	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.21e-05	0.000134	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NRAS—peripheral nervous system neoplasm	1.19e-05	0.000131	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—peripheral nervous system neoplasm	1.1e-05	0.000122	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.04e-05	0.000115	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.02e-05	0.000113	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.94e-06	0.00011	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.51e-06	0.000105	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HRAS—peripheral nervous system neoplasm	8.67e-06	9.61e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.4e-06	9.3e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT1—peripheral nervous system neoplasm	7.66e-06	8.49e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AKT1—peripheral nervous system neoplasm	6.41e-06	7.11e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AKT1—peripheral nervous system neoplasm	6.04e-06	6.69e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	4.66e-06	5.16e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	4.28e-06	4.75e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	4.25e-06	4.71e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	3.63e-06	4.02e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	2.8e-06	3.1e-05	CbGpPWpGaD
